(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 68.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Insmed's revenue in 2026 is $819,564,000.On average, 25 Wall Street analysts forecast INSM's revenue for 2026 to be $376,282,254,936, with the lowest INSM revenue forecast at $347,454,178,953, and the highest INSM revenue forecast at $414,647,438,763. On average, 25 Wall Street analysts forecast INSM's revenue for 2027 to be $619,261,752,507, with the lowest INSM revenue forecast at $488,343,272,103, and the highest INSM revenue forecast at $751,263,995,166.
In 2028, INSM is forecast to generate $844,901,053,998 in revenue, with the lowest revenue forecast at $588,266,152,014 and the highest revenue forecast at $1,134,699,080,985.